Quantcast

Latest Cell Therapeutics Inc. Stories

2014-05-30 04:22:11

SEATTLE, May 30, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI or the Company) (NASDAQ and MTA: CTIC), a biopharmaceutical company focused on acquiring, developing and bringing to market novel targeted therapies for blood-related cancers, today announced that it will change its corporate name to CTI BioPharma Corp. effective May 30, 2014. The Company's common stock will continue to trade under its current ticker symbol: "CTIC." http://photos.prnewswire.com/prnvar/20140529/92480...

2014-05-29 12:26:36

NEW YORK, May 29, 2014 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Cell Therapeutics, Inc. (NasdaqCM: CTIC) in connection with possible claims of breaches of fiduciary duty by certain members of the board of directors of the Company. http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO To get more information, click here: http://zlk.9nl.com/cell-therapeutics-ctic. There is no cost or obligation to you. If you own common stock in Cell Therapeutics, Inc. and wish...

2014-05-29 04:21:51

SEATTLE, May 29, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the Jefferies 2014 Global Healthcare Conference on Wednesday, June 4 at 11:30 a.m. PDT/2:30 p.m. EDT/8:30 p.m. CEST in New York. The presentation will be webcast live and available for replay from the Cell Therapeutics' website Investors section at www.celltherapeutics.com. About Cell Therapeutics Cell Therapeutics (NASDAQ and MTA: CTIC) is a...

2014-04-29 16:31:16

- Reports Net Product Sales Growth for PIXUVRI® Following Positive Reimbursement Decisions in Key E.U. Countries - SEATTLE, April 29, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014. "In the first quarter, we achieved growth in E.U. sales of PIXUVRI for the treatment of patients with aggressive B-cell non-Hodgkin lymphoma, which is due in part to the previously announced favorable...

2014-04-29 04:21:45

- First and Only Approved Monotherapy in the EU for this Patient Population - BIRMINGHAM, England, April 29, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54(th) annual scientific meeting of the British Society for Haematology. PIXUVRI...

2014-04-22 04:21:24

- Conference Call and Webcast at 4:30 p.m. Eastern Time - SEATTLE, April 22, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m....

2014-03-25 08:37:09

PHOENIX, March 25, 2014 /PRNewswire/ -- Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results. http://photos.prnewswire.com/prnvar/20100419/HKM001LOGO...

2014-03-05 04:22:19

SEATTLE, March 5, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26(th) Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA. The presentation will be webcast live and available for replay from the Cell Therapeutics' website Investors section at www.celltherapeutics.com. About Cell Therapeutics Cell Therapeutics (NASDAQ and MTA:...

2014-03-04 16:25:30

- 2014 Priorities: Complete and Report Top-line Results of First Pacritinib Phase 3 and Drive EU Sales of PIXUVRI - SEATTLE, March 4, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013. "2013 was a transformational year for CTI, as we entered into a worldwide license agreement with Baxter International to develop and commercialize our JAK2/FLT3 inhibitor, pacritinib, achieved...

2014-03-03 04:22:38

- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related